Skip to main content
main-content
Top

26-04-2010 | Cardiometabolic | Article

ApoB/AI ratio predicts microalbuminuria in prediabetics

Abstract

Free abstract

MedWire News: The ratio of apolipoprotein (apo) B to A-1 is a strong predictor for microalbuminuria in Korean men with impaired fasting glucose (IFG), study findings suggest.

Although a causal relationship remains to be proven, the researchers suggest that controlling the apoB/A-1 ratio may improve microalbuminuria and even reduce cardiovascular risk in prediabetic individuals.

The study, by Ki-Chul Sung (Kangbuk Samsung Hospital, Seoul, South Korea) and team, assessed the relationship between the apoB/A-1 ratio and microalbuminuria in 1266 apparently healthy men.

All participants had fasting serum glucose levels in the prediabetic range (100–126 mg/dl) and had urine samples analyzed for microalbuminuria (urine albumin-to-creatinine ratio of 30–299 µg/mg).

The likelihood of microalbuminuria increased in line with the apoB/A-1 ratio, report Sung et al in the journal Nutrition, Metabolism and Cardiovascular Disease. The prevalence was 1.6% among patients in the lowest apoB/A-1 quartile and 7.0% among those in the highest quartile, a statistically significant result.

Furthermore, the apoB/A-1 ratio was a significant predictor of microalbuminuria after adjusting for age, gender, and multiple cardiovascular risk factors, with an odds ratio of 4.2 for the highest versus the lowest quartile.

Finally, analysis of receiver operating characteristic curves revealed that the apoB/A-1 ratio had the greatest ability to detect microalbuminuria, followed by high-sensitivity C-reactive protein, a marker of chronic inflammation.

“Although causality could not be drawn, the study result raises the possibility that control of inflammation and/or controlling the apoB/A-1 ratio with specific interventions may improve microalbuminuria and may even reduce the increased cardiovascular mortality in patients with fasting hyperglycemia,” the study authors conclude.

“Prospective studies addressing the renal outcomes in subjects with elevated apoB/A-1 ratio are warranted.”

MedWire (www.medwire-news.md) is an independent clinical news service provided by Current Medicine Group, a trading division of Springer Healthcare Limited. © Springer Healthcare Ltd; 2010

By Joanna Lyford